Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
N K T HlaingR A MitraniS T AungW W PhyoM SerperA M M KyawA H BwaK M WinRajender K ReddyPublished in: Journal of viral hepatitis (2017)
DAA therapy ±PEG-IFN achieved high SVR rates. Genotype 6 patients had a low SVR to 12 weeks of LDV and SOF raising the need for other regimens, RBV or longer treatment duration in this population.